Healthy volunteers needed to test new eczema drug copy
NCT ID NCT07358156
First seen Jan 25, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This early-stage study tests a new drug called CKD-706, which is similar to the approved eczema treatment Dupixent. About 519 healthy adults will receive a single dose of either CKD-706, the US version of Dupixent, or the European version. The goal is to compare how the body processes each drug and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Parexel EPCU Berlin
NOT_YET_RECRUITINGBerlin, State of Berlin, 10115, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Parexel EPCU London
RECRUITINGLondon, England, HA1 3UJ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.